CYP1A1 and CYP3A4 polymorphic variations in Delhi population of Northern India

Kumar, Vivek; Singh, Satyender; Yadav, Chandrashekhar; Ahmed, Rafat S.; Gupta, Sanjay; Pasha, Syed Tazeen; Tripathi, Anil Kumar; Banerjee, Basu Dev

doi:10.1016/j.etap.2009.12.001

Cited by 23 publications

(15 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings in the present study are in line with previous study conducted on an Indian population [7]. However Kumar et al observed that CYP1A1 m1 polymorphism show no such significance in North Indian population of Delhi [8]. Similarly, studies conducted in various other ethnic Asian populations like Chinese [9] have also confirmed an association of the CYP1A1 m1 polymorphism with lung cancer development.…”

supporting

confidence: 94%

Combinations of the Variant Genotypes of CYP1A1, GSTM1 and GSTT1 are Associated with an Increased Lung Cancer Risk in North Indian Population: a Case-Control Study

Girdhar

Singh

Behera

et al. 2016

Pathol. Oncol. Res.

View full text Add to dashboard Cite

supporting

confidence: 94%

Combinations of the Variant Genotypes of CYP1A1, GSTM1 and GSTT1 are Associated with an Increased Lung Cancer Risk in North Indian Population: a Case-Control Study

Girdhar

Singh

Behera

et al. 2016

Pathol. Oncol. Res.

View full text Add to dashboard Cite

“…However, the rates with which these drugs are metabolized vary considerably in individual hepatic microsomes, and this variation is believed to be caused by CYP2B6 isoforms, besides the environmental factors such as the enzyme inducers. Clinical importance of genetic variations and role of ethnicity of CYP2D6 , CYP2C19 , CYP2C9, and CYP2D6 are well known (Adithan et al 2003; Anitha and Banerjee 2003; Kumar et al 2010; Lamba et al 1998ab) but CYP2B6 has only recently been recognized to code for a highly variable enzyme of potential clinical importance (Lang et al 2001; Lamba et al 2003). More than 100 DNA variations have been reported in CYP2B6 gene, and many of them show extensive linkage disequilibrium giving rise to distinct haplotypes.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of poor and rapid metabolizers of drugs metabolized by CYP2B6 in North Indian population residing in Indian national capital territory

Varshney

Saha²,

Tandon³

et al. 2012

SpringerPlus

View full text Add to dashboard Cite

Identification of poor and rapid metabolizers for the category of drugs metabolized by cytochrome P450 2B6 (CYP2B6) is important for understanding the differences in clinical responses of drugs metabolized by this enzyme. This study reports the prevalence of poor and rapid metabolizers in North Indian population residing in the National Capital Territory.The prevalence of poor and rapid metabolizers was determined in the target population for the category of drugs metabolized by CYP2B6 by measuring plasma bupropion, a drug metabolized by CYP2B6, and its metabolite. Bupropion (75 mg) was administered to 107 volunteers, and the drug (bupropion) and its metabolite (hydroxybupropion) were determined simultaneously by LCMS/MS in the plasma. CYP2B6 activity was measured as hydroxybupropion/bupropion ratio, and volunteers were categorized as rapid or poor metabolizers on the basis of cutoff value of log (hydroxybupropion/bupropion). Significant differences were observed between the mean metabolite/drug ratio of rapid metabolizers (Mean = 0.59) and poor metabolizers (Mean = 0.26) with p<0.0001. Results indicate that 20.56% individuals in the target population were poor metabolizers for the category of drugs metabolized by CYP2B6. Cutoff value defined in this study can be used as a tool for evaluating the status of CYP2B6 using bupropion as a probe drug. The baseline information would be clinically useful before administering the drugs metabolized by this isoform.

show abstract

“…The effect of CYP3A5*3 polymorphism on pharmacodynamic response to clopidogrel has not been established in our population so far. The CYP3A5*3 defective allele frequency is also higher in our population when compared to the expression of CYP3A4 [16]. The defective allele frequency of CYP3A5*1 and *3 alleles in the Tamilian population were 37 % and 63 % respectively.…”

Section: Introductionmentioning

confidence: 71%

Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population

Priyadharsini

Shewade

Subraja³

et al. 2014

Mol Biol Rep

View full text Add to dashboard Cite

Clopidogrel is an antiplatelet drug. It is used for the treatment as well as for the prophylaxis of coronary artery disease. Clopidogrel resistance is an emerging problem in clinical settings. The aim of the present study was to evaluate the effect of CYP3A5*3 genetic polymorphism on clopidogrel resistance. One hundred and forty-seven patients from outpatient Department of Cardiology on 75 mg/day of clopidogrel as maintenance dose were recruited from April 2010 to July 2011. All subjects gave written informed consent to participate in the study. DNA extraction was performed using phenol chloroform extraction procedure and genotyping by standard Taqman based RT-PCR method. Platelet aggregation was done at the end of 7th and 14th day by using chronolog lumi Aggregometer which is expressed as impedance in ohms. Impedance values of >5 ohms at the end of 6 min were considered as clopidogrel resistance. Subjects (N = 147) were analysed for CYP3A5*3 polymorphism, of which 49 (33%) were found to be clopidogrel resistant. Homomutants of CYP3A5*3 gene had 2.78 (0.97-7.98; p < 0.05) fold risk and heteromutants had 2.4 (0.93-6.46; p < 0.05) fold risk of developing clopidogrel resistance. Carriers of defective allele G of CYP3A5*3 had higher propensity to cause clopidogrel resistance with an odds ratio of 1.63. Variant alleles and genotypes of CYP3A5*3 polymorphism contributed significantly to clopidogrel resistance with a higher odds ratio. Thus, pharmacogenomics paves way for the emergence of stratified medicine in clopidogrel therapy and personalised pharmacotherapy in ischaemic heart disease.

show abstract

CYP1A1 and CYP3A4 polymorphic variations in Delhi population of Northern India

Cited by 23 publications

References 32 publications

Combinations of the Variant Genotypes of CYP1A1, GSTM1 and GSTT1 are Associated with an Increased Lung Cancer Risk in North Indian Population: a Case-Control Study

Combinations of the Variant Genotypes of CYP1A1, GSTM1 and GSTT1 are Associated with an Increased Lung Cancer Risk in North Indian Population: a Case-Control Study

Prevalence of poor and rapid metabolizers of drugs metabolized by CYP2B6 in North Indian population residing in Indian national capital territory

Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population

Contact Info

Product

Resources

About